Patient info Open main menu

Strepsils Strawberry Sugar Free Lozenges – Summary of Product Characteristics (SmPC) for healthcare professionals

Last updated: · Text from the MHRA, as of · About this document

Medicine status: General sale (GSL) Details

The Summary of Product Characteristics (SmPC) is written for healthcare professionals. Patients will find plain advice in the patient information leaflet: how to take, side effects, pregnancy and breast-feeding.

Medicine strength:
1.2 mg + 600 microgram
Contains active substances:

Summary of Product Characteristics (SmPC) - Strepsils Strawberry sugar free lozenges

1 NAME OF THE MEDICINAL PRODUCT

Strepsils Strawberry Sugar Free Lozenges

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Active Ingredients

Amylmetacresol 0.6mg/lozenge

2,4-Dichlorobenzyl alcohol 1.2mg/lozenge

Excipient(s) with known effect:

Propylene glycol (present in strawberry flavour)

Fragrance containing allergens – Benzyl Alcohol (present in strawberry flavour) Isomalt

Maltitol syrup

For a full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Lozenge

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

As an antiseptic for the relief of sore throat and its associated pain.

4.2 Posology and method of administration

Posology

Use the lowest dose for the shortest duration necessary to relieve symptoms.

Adults:

One lozenge every 2-3 hours up to a maximum of

12 lozenges in 24 hours.

Elderly:

There is no need for dosage reduction in the elderly

Children over 6 years old:

As above for adults.

Children under 6 years old:

Not suitable for children under 6 years (see section 4.4).

Method of Administration

For oral administration. To be dissolved slowly in the mouth.

4.3 Contraindications

Strepsils Strawberry Sugar Free Lozenges are contraindicated in persons who have previously shown hypersensitivity to any of the ingredients. The product contains a small amount of butylated hydroxyanisole (BHA; E320)

4.4 Special warnings and precautions for use

Not to be given to children under 6 years.

If symptoms persist have not improved, or have worsened after 3 days, or if symptoms persist or are accompanied by a high fever or headache, consult a doctor or health care professional.

Important information about some of the ingredients of this medicine:

  • Contains isomalt and maltitol syrup, which may have a mild laxative effect if several are taken a day. Patients with rare hereditary problems of fructose intolerance should not take this medicine.
  • This medicine contains 7.30 mg propylene glycol (present in strawberry flavour) in each lozenge.
  • This medicine contains fragrance Benzyl Alcohol. Benzyl Alcohol may cause allergic reactions.
  • This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free’.

4.5 Interaction with other medicinal products and other forms of interaction

None known.

4.6 Fertility, pregnancy and lactation

Pregnancy

There are no or limited amount of data from the use of amylmetacresol and 2,4-dichlorbenzyl alcohol.

As with all medicines care should be taken when using this product in pregnancy and medical advice sought if necessary.

Breast-feeding

It is unknown whether 2,4-dichlorobenzyl alcohol, amylmetacresol or metabolites are excreted in human milk. A risk to the newborns / infants cannot be excluded.

Fertility

No data are available regarding the effects on fertility.

4.7 Effects on ability to drive and use machines

No or negligible influence on the ability to drive and use machines.

4.8 Undesirable effects

The list of the following adverse effects relates to those experienced with 2,4-dichlorobenzyl alcohol and amylmetacresol at OTC doses, in short term use.

Adverse events which have been associated with 2,4-dichlorobenzyl alcohol and amylmetacresol are given below, tabulated by system organ class and frequency. Frequencies are defined as: Very common (≥1/10); Common (≥1/100 and <1/10); Uncommon (≥1/1000 and <1/100); Rare (≥1/10,000 and <1/1000); Very rare (<1/10,000); Not known (cannot be estimated from the available data). Within each frequency grouping, adverse events are presented in order of decreasing seriousness.

System Organ ClassFrequencyAdverse Events
Immune System DisordersNot knownHypersensitivityab1
Gastrointestinal DisordersNot knownGlossodyniaab, oral discomfortab

a2,4-dichlorobenzyl alcohol bamylmetacresol

1 Hypersensitivity reactions may include rash, urticaria and angioedema, which may include swelling of the face, neck, throat or tongue that could affect breathing.

Reporting of Suspected Adverse Reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

In view of the nature and presentation of Strepsils Strawberry Sugar Free Lozenges, accidental or deliberate overdosage is highly unlikely.

Overdosage should not present a problem other than gastrointestinal discomfort. Treatment should be symptomatic.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Throat Preparations; Antiseptics; ATC Code: R02AA03 Dichlorobenzyl alcohol.

2,4-Dichlorobenzyl alcohol and amylmetacresol have antiseptic properties.

5.2 Pharmacokinetic properties

No data available.

5.3 Preclinical safety data

There are no preclinical data available specific to the product.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Flav P Strawberry Flavour (containing propylene glycol, Fragrance allergen Benzyl Alcohol)

Anthocyanins (E163)

Saccharin sodium Ph Eur (E954)

Tartaric acid Ph Eur

Isomalt (Isomaltitol E953)

Maltitol syrup (E965)

6.2 Incompatibilities

Not applicable

6.3 Shelf life

2 years

6.4 Special precautions for storage

Do not store above 25°C

6.5 Nature and contents of container

The lozenges are contained in a strip pack containing either 6, 8, 12, 16, 20, 24, 32 or 36 lozenges packed into a cardboard carton.

The lozenges are contained in a strip pack containing 8 lozenges packed into a wrap around cardboard carton with tamper-evident seal.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

None

7 MARKETING AUTHORISATION HOLDER

Reckitt Benckiser Healthcare (UK) Ltd

Slough

SL1 3UH

8 MARKETING AUTHORISATION NUMBER(S)

PL 00063/0395

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE

AUTHORISATION

06/04/2010

10 DATE OF REVISION OF THE TEXT

23/02/2021

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 00063/0395

Last revision stated in the text: 23 February 2021 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Strepsils Strawberry sugar free lozenges

Prescription needed? No, general sale list medicine (GSL) – also sold outside pharmacies
Active substances Amylmetacresol, Dichlorobenzyl alcohol
Strength 1.2 mg + 600 microgram
Pharmaceutical form Lozenge
How is it taken Oromucosal
Excipients Flav P Strawberry Flavour (containing propylene glycol, Fragrance allergen Benzyl Alcohol), Anthocyanins (E163), Saccharin sodium Ph Eur (E954), Tartaric acid Ph Eur, Isomalt (Isomaltitol E953), Maltitol syrup (E965)
Pack sizes 36 lozenge
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 2 years
Storage Do not store above 25°C
Drug group (ATC) Throat Preparations; Antiseptics
  1. R Respiratory system drugs
    1. R02 Throat preparations
      1. R02A Throat preparations
        1. R02AA Antiseptic throat preparations
          1. R02AA03 dichlorobenzyl alcohol
Marketing authorisation PL 00063/0395 (first authorised 6 April 2010)
Marketing authorisation holder Reckitt Benckiser Healthcare (UK) Ltd
Codes GTIN 5000158101364 · BNF 12030300

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.1.0 of 12 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.